Hyperhidrosis is a condition of excessive sweating beyond what is physiologically required to maintain normal thermal regulation. Several studies have demonstrated that excessive sweating often impedes normal daily activities and can result in occupational, emotional, psychological, social and physical impairment.
In the United States, based on the most recent data available, the prevalence of hyperhidrosis was estimated to be 2.8% of the population, or roughly 7.8 million people. Primary hyperhidrosis, which is excessive sweating without a known cause, is localized and characteristically symmetric. It can affect the underarms, or axillae, palms of the hands, soles of the feet, face and other areas. According to published studies, approximately half of hyperhidrosis sufferers have axillary hyperhidrosis.
The market for sweat controlling products is large and highly underpenetrated by prescription pharmaceutical products. Only 38% of hyperhidrosis patients have discussed their condition with a healthcare professional, according to a survey by the International Hyperhidrosis Society. We believe that this is largely due to the lack of effective, well-tolerated, convenient prescription treatment options. The most commonly prescribed treatments are topical antiperspirants. While these products generate over 500,000 prescriptions annually in the United States, their use is limited by modest efficacy and skin irritation.
Therapeutic options for patients who are unsatisfied with topical antiperspirants are largely limited to more cumbersome or invasive treatment strategies directed to blocking the activation of, destroying or removing the sweat glands. These treatments are time-consuming, and for the treating physician, can require a significant investment of training and administration time and may require capital investment, limiting their potential reach.
As a result of the limitations of available treatments, we believe that there is a significant unmet need for a new, effective, well-tolerated, self-administered, topical hyperhidrosis therapy that can be used across the range of body areas that can be affected by the disease. We believe that the market opportunity for this type of treatment is substantially larger than the current market for prescription topical antiperspirants because such a therapy could further penetrate the segment of patients who seek treatment from a physician, as well as encourage more patients to seek treatment.
For more information on excessive sweating, please see the International Hyperhidrosis Society website: www.sweathelp.org